Harmony Biosciences Holdings, Inc. provided Preliminary revenue guidance for the Fourth Quarter and Full Year 2023 and for the year 2024. The net product revenue for the quarter ended December 31, 2023, was approximately $168 million, compared to $128.3 million for the same period in 2022, representing approx. 31% growth.

The net product revenue for the full year ended December 31, 2023, was approximately $582 million, compared to $437.9 million for the same period in 2022, representing approx. 33% growth.

The company also provided 2024 net product revenue guidance of $700 to $720 million.